Textiles & Apparel Global On demand · 24-48h

Global Silk Fibroin (SF) Market Strategic Research Report

Global Silk Fibroin (SF) Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Silk Fibroin (SF) Market
$1222025
6.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Silk Fibroin Powder, Silk Amino Acids, Silk Peptide

By Application: Cosmetic & Personal Care, Biomedical, Supplements

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Seidecosa, Sofregen Inc, Caresilk, Cocoon Biotech, Kelisema Srl, CPT Sutures, Hanzhou Linran, Huzhou Xintiansi Bio-tech, Chongqing Haifan Biochemical, Suzhou Suhao Bio, Zhejiang Xingyue Biotechnology

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 111 pages
Market size 2025
$122
Million USD
Forecast CAGR
6.1%
2025-2032
Forecast 2032
$184.7
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global Silk Fibroin (SF) market size is predicted to grow from US$ 122 million in 2025 to US$ 183 million in 2032; it is expected to grow at a CAGR of 6.1% from 2026 to 2032.

Silk fibroin is a nature biomaterial derived from cocoon and silk. Studies have found that silk fibroin have the advantages of green processing, excellent biocompatibility, high molecular weight, and tissue repair characteristic.

Silk fibroin is widely used in the cosmetics, personal care, biomedicine and other industries. With the growth of demand in the biomedicine field and the expansion of the cosmetics and skin care market, the extraction, purification and application technology of silk fibroin is constantly improving under the progress of materials science and biotechnology, and the market of silk fibroin will grow steadily.

Silk fibroin has high nutritional value and is used in health-related products such as food additives and health products. This trend has further promoted the market demand for silk fibroin.

This report presents a comprehensive overview of the global Silk Fibroin (SF) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Silk Fibroin Powder
  • Silk Amino Acids
  • Silk Peptide

Segment by Application

  • Cosmetic & Personal Care
  • Biomedical
  • Supplements

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Silk Fibroin (SF) market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Cosmetic & Personal Care, Biomedical, Supplements evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Silk Fibroin (SF) Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$122
2025
Forecast
$184.7
2032
CAGR
6.1%
2025–2032
Régions
5
global
Key companies
SeidecosaSofregen IncCaresilkCocoon BiotechKelisema SrlCPT SuturesHanzhou LinranHuzhou Xintiansi Bio-tech
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Silk Fibroin PowderSilk Amino AcidsSilk Peptide
By Application
Cosmetic & Personal CareBiomedicalSupplements

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Silk Fibroin Powder
  • 3.1.3 Silk Amino Acids
  • 3.1.4 Silk Peptide
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Cosmetic & Personal Care
  • 4.1.3 Biomedical
  • 4.1.4 Supplements
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Seidecosa
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Sofregen Inc
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Caresilk
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Cocoon Biotech
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Kelisema Srl
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 CPT Sutures
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Hanzhou Linran
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Huzhou Xintiansi Bio-tech
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Chongqing Haifan Biochemical
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Suzhou Suhao Bio
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Zhejiang Xingyue Biotechnology
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Silk Fibroin (SF) market?
The global Silk Fibroin (SF) market is estimated at US$ 122 million in 2025 (base year) and is projected to reach US$ 183 million by 2032.
What is the forecast CAGR for the Silk Fibroin (SF) market?
The market is expected to grow at a CAGR of 6.1% from 2026 to 2032, expanding from US$ 122 million in 2025 to US$ 183 million in 2032, roughly 1.5 times its base-year value.
What is Silk Fibroin (SF)?
Silk fibroin is a nature biomaterial derived from cocoon and silk. Studies have found that silk fibroin have the advantages of green processing, excellent biocompatibility, high molecular weight, and tissue repair characteristic.
What are the main segments of the Silk Fibroin (SF) market by type?
By type, the market is segmented into Silk Fibroin Powder, Silk Amino Acids and Silk Peptide.
Which applications drive demand in the Silk Fibroin (SF) market?
Key applications covered include Cosmetic & Personal Care, Biomedical and Supplements.
Who are the key players in the Silk Fibroin (SF) market?
Key players profiled include Seidecosa, Sofregen Inc, Caresilk, Cocoon Biotech, Kelisema Srl, CPT Sutures, Hanzhou Linran and Huzhou Xintiansi Bio-tech, among 11 companies covered in total.
Which regions and countries are covered for Silk Fibroin (SF)?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Silk Fibroin (SF) market report?
The report is intended for manufacturers and solution providers, distributors and end users in Cosmetic & Personal Care, Biomedical and Supplements, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Silk Fibroin (SF) market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.